(0.08%) 5 521.50 points
(0.12%) 39 891 points
(0.19%) 19 789 points
(0.00%) $81.63
(0.43%) $2.82
(-0.30%) $2 337.40
(0.03%) $29.54
(0.36%) $1 005.40
(0.01%) $0.931
(0.01%) $10.53
(0.00%) $0.788
(-0.85%) $87.25
0.00% $ 54.99
Live Chart Being Loaded With Signals
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs...
Stats | |
---|---|
Dzisiejszy wolumen | 0 |
Średni wolumen | 651 457 |
Kapitalizacja rynkowa | 0.00 |
EPS | $-1.330 ( Q1 | 2022-05-06 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-8.34 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.324 (0.59%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-07-01 | Vivo Opportunity, Llc | Sell | 431 947 | Common Stock |
2022-07-01 | Vivo Opportunity, Llc | Sell | 75 749 | Series A Warrants |
2022-07-01 | Orbimed Advisors Llc | Sell | 226 704 | Common Stock |
2022-07-01 | Orbimed Advisors Llc | Sell | 170 437 | Series A Warrants |
2022-07-01 | Ashiya Mona | Sell | 226 704 | Common Stock |
INSIDER POWER |
---|
-98.43 |
Last 99 transactions |
Buy: 4 604 902 | Sell: 10 646 034 |
Wolumen Korelacja
Sierra Oncology Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sierra Oncology Inc Korelacja - Waluta/Towar
Sierra Oncology Inc Finanse
Annual | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-7.14 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-7.14 |
FY | 2020 |
Przychody: | $300 000 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-7.70 |
FY | 2019 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-30.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sierra Oncology Inc
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej